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Abstract
Background—Previous studies have reported that hyperthyroid and hypothyroid women 
experience menstrual irregularities more often compared with euthyroid women, but reasons for 
this are not well understood and studies on thyroid hormones among euthyroid women are lacking. 
In a prospective cohort study of euthyroid women, this study characterized the relationship 
between thyroid hormone concentrations and prospectively-collected menstrual function 
outcomes.
Methods—Between 2004–2014, 86 euthyroid premenopausal women not lactating or taking 
hormonal medications participated in a study measuring menstrual function. Serum thyroid 
hormones were measured before the menstrual function study began. Women then collected first 
morning urine voids and completed daily bleeding diaries every day for three cycles. Urinary 
estrogen and progesterone metabolites (estrone 3-glucuronide (E13G) and pregnanediol 3-
glucuronide (Pd3G)) and follicle-stimulating hormone were measured and adjusted for creatinine 
(Cr).
Results—Total thyroxine (T4) concentrations were positively associated with Pd3G and E13G. 
Women with higher (vs. lower) T4 had greater luteal phase maximum Pd3G (Pd3G=11.7 μg/mg Cr 
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for women with high T4 vs. Pd3G=9.5 and 8.1 μg/mg Cr for women with medium and low T4, 
respectively) and greater follicular phase maximum E13G (E13G=41.7 ng/mg Cr for women with 
high T4 vs. E13G=34.3 and 33.7 ng/mg Cr for women with medium and low T4, respectively).
Conclusions—Circulating thyroid hormone concentrations were associated with subtle 
differences in menstrual cycle function outcomes, particularly sex steroid hormone levels in 
healthy women. Results contribute to the understanding of the relationship between thyroid 
function and the menstrual cycle, and may have implications for fertility and chronic disease.
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Introduction
Menstrual cycle function is determined by a complex endocrine axis that controls the ovaries 
and endometrium and represents the underlying hormonal milieu of the female reproductive 
system. Menstrual cycle function characteristics such as cycle length have been found to be 
associated with reproductive health and fertility.1, 2 Therefore, menstrual cycle 
characteristics provide non-invasive markers of endocrine and reproductive health, making 
them useful for epidemiologic research.
The menstrual cycle is governed by a network of gonadotropins (e.g., luteinizing hormone 
(LH) and follicle-stimulating hormone (FSH)) and sex steroid hormones (e.g., estrogens and 
progesterone); key constituents of the hypothalamic-pituitary-gonadal axis. This system is 
closely related to the hypothalamic-pituitary-thyroid axis, which controls thyroid function.3 
However, the relationship between thyroid function and female reproductive physiology is 
complex. Women are more likely to develop thyroid disease than men, and incidence is 
greatest during times of hormonal flux, such as menopause, puberty, and pregnancy, which 
may indicate a role of estrogens.4
Both hypothyroid and hyperthyroid women have been reported to have a greater prevalence 
of menstrual disturbances compared with euthyroid women.5–7 Specifically, hypothyroid 
women are more likely to experience oligomenorrhea and menorrhagia;6, 8, 9 and 
hyperthyroid women are more likely to experience hypomenorrhea compared with euthyroid 
women.5, 8 However, much of the research on this topic to date has been limited to clinic-
based studies that compare women with severe forms of thyroid disease (e.g., thyrotoxicosis 
and myxedema) with euthyroid women, and few have measured thyroid hormones.6 In 
addition, many of these studies have relied upon self-reported data of menstrual cycle 
outcomes assessed at one time-point, and have often consolidated different outcomes 
together as menstrual “disturbances” or “irregularities”.8, 10 Therefore, the intricacies of the 
relationship between thyroid function and menstrual physiology remain unclear.
The purpose of this study was to characterize the relationship between serum thyroid 
hormones and specific menstrual cycle function outcomes using prospectively collected 
menstrual function data and urinary hormone levels across several cycles in a sample of 
euthyroid, premenopausal women. The associations between serum thyroid hormone 
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concentrations and several indicators of menstrual cycle function were evaluated across 
multiple cycles: cycle-specific characteristics, several multi-day gonadotropin and steroid 




The Michigan Polybrominated Biphenyl (PBB) Registry is a study of the long-term health 
outcomes of a population that was exposed to persistent organic pollutants in the early 1970s 
through a contamination of the food supply.11 A subset of women in this cohort were 
recruited to participate in a longitudinal study on menstrual cycle function.
Participants for the menstrual cycle function study were recruited between 2004–2006 and 
2013–2014. To be eligible, women had to be premenopausal, not pregnant or lactating, not 
currently taking hormonal medications, and never diagnosed with or treated for cancer. 
Participation entailed a blood draw; completion of a health questionnaire with details on 
medical history (including report of physician-diagnosed thyroid disease), current 
medication use, behaviors, and demographics; and menstrual cycle function monitoring 
which included daily urine collections and daily diaries (see Menstrual cycle function 
protocol). This study was approved by the Institutional Review Boards at Emory University 
and the State Health Department of Michigan.
Thyroid hormones
Thyroid hormone levels were measured in serum of study participants without a history of 
thyroid disease and who were not currently taking thyroid-disrupting medication. Thyroid-
stimulating hormone (TSH), total and free thyroxine (T4), and total and free triiodothyronine 
(T3) were analyzed at the Emory Clinical Translational Research Laboratory with the 
Beckman Coulter Access II chemiluminescent immunoassay analyzer (Beckman Coulter, 
Brea, CA). Analyses were conducted as directed by the manufacturer. Daily quality control 
samples were run before and after all study samples, and blinded controls were run 
throughout. If QC samples were more than two standard deviations from the expected 
values, the assay was repeated. Coefficients of variation for thyroid hormone assays are 
shown in Table S1.
Menstrual cycle function protocol
Women were asked to keep daily menstrual diaries and collect first morning urine void 
samples every day for at least three menstrual cycles (defined as four menstrual periods or 
18 weeks for oligomenorrheaic or amenorrheic women). The diaries included daily 
information on bleeding, menstrual cramping, stress, smoking and alcohol consumption, 
exercise habits, and medication use (Figure S1). In urine samples from women recruited in 
2004–2006, the estrogen and progesterone metabolites, estrone 3-glucuronide (E13G) and 
pregnanediol 3-glucuronide (Pd3G), respectively, were measured in a 17-day window 
around expected ovulation (preceding the last 4 days of the cycle). In women with sufficient 
data during the luteal-follicular transition (n=29 of 32 women recruited between 2004–
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2006), E13G, Pd3G, and FSH were also measured in this 10-day window, which included 
menses onset (5 days before menses onset through cycle day 4 of the next cycle). Day of 
ovulation was based on identifying a day of luteal transition (DLT), which was determined 
by an algorithm examining changes in the ratio of E13G to Pd3G.12 In urine samples from 
women recruited in 2013–2014, E13G and Pd3G were measured every day and FSH was 
measured in the same 10-day window during the luteal-follicular transition, which included 
menses onset. Ovulatory cycles were again defined the presence of a DLT and were 
validated against urinary LH measurements conducted in a 10-day mid-cycle window due to 
the common clinical use of LH as a marker of ovulation.13
Urinary E13G and Pd3G were measured in triplicate using competitive double-antibody 
time-resolved fluoroimmunoassays.14 Urinary LH and FSH were assayed in duplicate using 
immunofluorometric assays (PerkinElmer, Waltham, MA, USA; Cat. Nos. A031–101 and 
A017–201, respectively) modified and validated for analyzing urine samples.15, 16 Urinary 
creatinine (Cr) was measured using a Vitros 250 Chemistry Analyzer (Ortho-Clinical 
Diagnostics, Raritan, NJ, USA).17, 18 Urinary endocrine concentrations were divided by Cr 
concentrations to normalize for sample dilution.
Menstrual cycle function outcomes
Menstrual cycle function outcomes included cycle-level characteristics: cycle length, bleed 
length and intensity, and follicular and luteal phase lengths; multi-day hormonal outcomes 
calculated as 3-day geometric means (GM) of FSH, Pd3G, and E13G at various times 
throughout the cycle (Table S2); and day-specific E13G, Pd3G, and FSH levels throughout 
the cycle. Anovulation was also of interest but we did not have the power to examine this 
potential association. Four cycles from 3 different women showed evidence of anovulation, 
which constituted 1.6% of cycles that had sufficient mid-cycle samples to detect potential 
ovulation.
Menses onset was defined as the first of 2 consecutive days of bleeding, only one of which 
could be spotting, and which was preceded by 3 consecutive days of non-bleeding or 
spotting.19 Cycle length was defined as the first day of menses through the day before 
menses onset in the next cycle. In order to characterize within-woman variability in 
menstrual cycle length, we calculated the standard deviation of cycle length for each woman 
who contributed ≥2 cycles. Bleed intensity was the arithmetic mean of self-reported bleeding 
(0=no bleeding, 1=spotting, 2=light, 3=moderate, 4=heavy) over the course of menses. The 
follicular phase was defined as the first day of menses through the day of ovulation. The 
luteal phase was the day after ovulation through the day before menses onset.20
The hormonal outcomes were adapted from definitions proposed by Baird et al. that were 
shown to be related to conception.21 Maximum 3-day GMs were calculated for the follicular 
phase and the luteal phase only when no samples were missing during each relevant 
timeframe; thus sample sizes for each analysis varied by outcome (mostly due to women 
who missed single days of urine collection).
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Among women who did not report a history of physician-diagnosed thyroid disease and/or 
current thyroid medication use, we explored the distribution of each thyroid hormone in 
univariate analyses and by each covariate stratum. TSH was log-transformed to approximate 
a normal distribution.
For models where there was one outcome per cycle (cycle-level characteristics and 3-day 
GMs), we fit linear mixed models with a random effect for woman in order to account for 
the intra-individual correlations among multiple menstrual cycles per woman. We evaluated 
associations between each individual thyroid hormone and each menstrual cycle outcome, 
adjusting for age as a fixed effect. Thyroid hormones were fit as fixed effects and were 
expressed continuously in all our final models, with both a linear and quadratic term to allow 
for flexibility with each outcome. Estimates were output for the 12.5th (low), 50th (medium) 
and 87.5th (high) percentile of each hormone. We also adjusted for body mass index (BMI) 
and smoking, but because results did not change, we present results only controlling for age. 
For cycle-level characteristics, we generated predicted means of each characteristic for a 
woman of mean age in our study (38 years). For the 3-day GM outcomes, we present 
comparisons (via β-coefficients) between the low (12.5th percentile) and medium (50th 
percentile) and high (87.5th percentile) and medium (50th percentile) thyroid hormone levels. 
Medium was treated as the reference because as it has been reported that both hypothyroid 
and hyperthyroid women experience menstrual cycle disruption compared to euthyroid 
women,7 we aimed to assess impacts at the lower end as well as the higher end of each 
thyroid hormone distribution and compare them with median levels
We also examined the associations between each thyroid hormone and day-specific E13G, 
Pd3G, and FSH by fitting linear mixed models with random effects for woman and cycle to 
account for the nesting of days within cycles and cycles within women. E13G, Pd3G, and 
FSH levels were adjusted for creatinine and natural log-transformed. Models for E13G and 
Pd3G were aligned by the estimated day of ovulation ± 10 days and for E13G, Pd3G, and 
FSH by menses onset (5 days before menses onset through cycle day 4 of the next cycle). 
We adjusted for age and present the predicted daily log-transformed E13G, Pd3G, and FSH 
levels by each thyroid hormone category (low (minimum-25th percentile), medium (25th 
percentile–75th percentile), and high (75th percentile-maximum) over each relevant 
timeframe for a 38-year old (mean-aged) woman.
Results
A total of 93 women had their blood drawn, completed a questionnaire, and collected 
menstrual cycle function data consisting of both urine samples and corresponding daily 
diaries. Seven women (7.5%) reported a previous thyroid disease diagnosis (n=5 
hypothyroid, n=1 Hashimoto’s thyroiditis, and n=1 type not specified), were currently taking 
thyroid medication, and were thus excluded from further analyses. The remaining women 
(n=86) collected data for a total of 423 cycles and 65.0% of these were complete cycles 
(n=275), meaning that diary data indicated a start and end to the cycle and daily menstrual 
function monitoring (urine samples and diary entries) occurred during the vast majority of 
days during the cycle. Among these 275 cycles, 64.4% had no missing urine samples; 24.0% 
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had between 1 and 3 missing samples, and the remainder (11.6%) were missing four or 
more. Individual women contributed between 1 and 9 complete cycles, with a median of 3 
complete cycles (interquartile range=3–4). Women were between 18 and 53 years old 
(mean=38 years), and a substantial proportion (40.7%) between 36–40 years (Table 1). Most 
women had completed at least some college (84.7%), had previously been pregnant (77.9%), 
and were never smokers (59.3%).
Table 2 shows the distribution of thyroid hormones among the 86 women never diagnosed 
with thyroid disease. Hormone levels for one woman (TSH=0.06 μIU/ml, total T4= 12.1 
μg/dl, total T3= 148 ng/dl, free T4= 1.24 ng/dl, free T3= 3.73 pg/ml) met the clinical 
definition of hyperthyroidism. All others had hormones within the euthyroid range.
Women aged 18–29 had longer cycles and follicular phases and greater cycle length 
variability than women in their thirties (Table S3). Bleed length and intensity decreased with 
age. Former and current smokers had shorter cycles compared with never smokers. Obese 
women had longer cycles than overweight and normal weight women. Overweight and 
obese women had shorter bleeds than normal weight women. Women aged 41–54 had higher 
FSH in the late luteal phase and early follicular phase, and lower Pd3G and E13G at various 
timeframes across the cycle compared with younger women (Table S4). Current smokers 
showed similar patterns compared with never and former smokers even after controlling for 
age. No consistent patterns between participant characteristics and thyroid hormones were 
observed (Table S5).
Thyroid hormone levels were not associated with cycle or phase lengths and effect estimates 
were small (Table 3). However, there was a suggestion that lower free T4 was associated 
with decreased cycle length compared with higher free T4. Although the predicted mean 
cycle lengths increased with increasing free T4 (low: 28.2 days (95% confidence interval 
[CI] 23.9, 32.5; medium: 31.1 days (95% CI 27.6, 34.5); high: 32.1 days (95% CI 27.6, 
36.5)), the differences were small and the confidence intervals overlapped substantially. 
These subtle differences in cycle length were due to variation in follicular phase length, 
which showed a similar pattern with free T4, while luteal phase lengths remained consistent 
across groups. Bleed length and intensity were not associated with thyroid hormone levels. 
Although adjusting for smoking status and BMI did not influence the effect estimates for 
thyroid hormones (data not shown), the predicted cycle-level characteristics were different 
between smoking and BMI strata, which suggests that these factors were independently 
associated with these menstrual cycle characteristics. In addition, results did not change 
when we excluded the one woman who met the clinical definition of hyperthyroidism based 
on her thyroid hormone assay results (data not shown).
Table 4 shows the associations between thyroid hormone concentrations and the multi-day 
hormonal outcomes for FSH, Pd3G, and E13G. Total T4 was consistently associated with 
greater Pd3G and E13G across various 3-day intervals (follicular phase maximum E13G and 
luteal phase maximum Pd3G, preovulatory E13G, and mid-luteal phase Pd3G and E13G). 
Estimated differences in E13G and Pd3G were largest between those with high and medium 
total T4 levels. This pattern was also apparent across the cycle when considered in day-level 
analyses (Figure 1). Women with high levels of total T4 had greater predicted concentrations 
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of Pd3G throughout the follicular and luteal phases compared with those with medium and 
low T4, and this difference was smallest around the time of ovulation (Figure 1, panel A). 
Furthermore, lower total T4 was associated with lower Pd3G at various points during the 
cycle, as evidenced by lower 3-day GMs though not statistically significant, as well as lower 
daily levels throughout the cycle, especially in the follicular phase (Figure 1, panels A and 
B). Total T4 was also positively associated with E13G throughout the cycle (Figure 1, panels 
C and D). Women with higher total T4 concentrations had greater E13G levels compared 
with those with lower total T4 concentrations, although differences were smaller than for 
Pd3G. Free T4 was not associated with these endocrine levels.
Total and free T3 were also associated with both Pd3G and E13G levels. In particular, higher 
total and free T3 were associated with greater concentrations of E13G at various timeframes 
throughout the cycle. For example, preovulatory levels of E13G were greater for women 
with high total T3 (E13G=35.1 ng/mg Cr, 95% CI 33.4, 50.0) compared with those with 
medium total T3 (E13G=26.8 ng/mg Cr, 95% CI 22.5, 31.2). Similarly, those with high free 
T3 had greater E13G (33.7 ng/mg Cr, 95% CI 32.3, 42.6) than those with medium free T3 




In a cohort of premenopausal euthyroid women, thyroid hormone levels were evaluated in 
relation to prospectively collected menstrual cycle function outcomes. To our knowledge, 
this is the first study to assess these relationships. Greater total T4 was associated with 
higher Pd3G and E13G levels throughout the cycle, and lower total T4 was associated with 
lower Pd3G especially during the follicular phase. Total and free T3 were also positively 
correlated with Pd3G and E13G levels at several times during the cycle. There was also a 
suggestion that free T4 was associated with shorter cycle and follicular phase length. These 
observations were consistent when controlling for multiple potential confounders, excluding 
an outlier with biochemical evidence of undiagnosed hyperthyroidism, and considering 
hormonal outcomes as 3-day means as well as day-specific measures.
Interpretation
Studying the relationship between thyroid hormones and menstrual cycle function is 
complex because while it has been repeatedly noted in clinical studies that women with 
thyroid diseases experience disruption of their menstrual cycles, it is also well understood 
that steroid hormones can affect thyroid hormones. For example, during pregnancy, elevated 
estrogen levels lead to increased total T4 due to thyroxine-binding globulin (TBG).22 In this 
study, total T4 was positively correlated with E13G and Pd3G throughout the cycle. 
Although this study was prospective in design and serum samples for measuring thyroid 
hormones were collected before the menstrual cycle function monitoring began, it may be 
possible that pre-existing steroid hormone levels led to a state of greater total T4 
concentrations, perhaps due to greater levels of TBG. Therefore, even given this longitudinal 
study design, it is difficult to parse out the directionality of these relationships.
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One study that conducted a post-hoc analysis of a randomized controlled trial found that 
women on progesterone therapy had increased free T4 after therapy compared with those 
who received placebo.23 This observed correlation between progesterone and thyroxine 
could be due to a shared pathway within metabolic processes for increasing basal body 
temperature and energy expenditure. These hormones are also both transported by albumin, 
although albumin carries only about 10% of circulating thyroxine, with its main transporter 
being TBG.24
The positive association between total T4 and E13G is consistent with previous observations 
of higher plasma estrogen levels throughout the menstrual cycle among hyperthyroid women 
compared with euthyroid controls.25, 26 It has been hypothesized that this may be due to T4-
induced increases in sex-hormone binding globulin, which leads to increases in serum levels 
of estrogen and decreased clearance rates.5, 26 However, another potential mechanism may 
be the increased androgen production and subsequent increased conversion of androgens to 
estrogens that occurs among hyperthyroid women.27 In this study, a similar association was 
noted despite the significant differences in study design and population: women had thyroid 
hormone levels within the euthyroid range and urinary estrogen metabolites were measured 
as opposed to plasma or serum estradiol concentrations.
If the relationships between thyroid hormones and menstrual cycle function are causal, these 
findings may be relevant to exogenous factors that influence thyroid function. For example, 
to the extent that environmental toxicants and personal behaviors such as smoking may 
affect thyroid function,28, 29 menstrual cycle outcomes and female reproduction may also in 
turn be affected through this pathway. However, in this study, personal exposures such as 
smoking were not strongly related to thyroid hormone concentrations. Alternatively, it is 
possible that if an exogenous factor affected both thyroid function and menstrual cycle 
function independently, this could induce an association between thyroid hormones and 
menstrual cycle function or make the associations vary across strata of this other factor. 
Women in this study were exposed to a persistent organic pollutant (PBB) and most (89%) 
had detectable levels of PBBs in their blood. However, when controlling for PBB in models 
or restricting analyses to women with PBB levels below the median, results did not change 
(data not shown). In conjunction with the results being consistent with those of other studies 
conducted among unexposed women, this strengthens the hypothesis that there is a direct 
and causal relationship between thyroid hormones and menstrual cycle function.
Strengths of the study
This study benefited from prospective collection of menstrual cycle function data over 
multiple cycles per woman. This type of monitoring has several advantages over self-report 
of “usual” menstrual characteristics in that it improves accuracy and precision,19, 30 thereby 
reducing the likelihood of misclassification, and it incorporates a degree of within-woman 
variability due to observations over multiple cycles. In addition, the assessment of menstrual 
cycle function was comprehensive; several reproductive endocrine analytes were measured 
in addition to cycle characteristics. Finally, age, smoking, and BMI were related to cycle 
characteristics as well as several reproductive hormone levels, as reported in the literature.
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31–34 These observations lend additional support to the validity of the menstrual cycle 
function data.
Limitations of the data
This study had some limitations as well. First, it was limited by small sample size even 
though there were multiple cycles per woman. The detailed data on menstrual cycle function 
is reflected in a demanding study protocol, which was a contributing factor to the small 
number of women who participated in the study. This limited sample size prevented 
thorough investigation of potential effect measure modification by several characteristics 
that are known to affect menstrual cycle function parameters, such as age. It is theoretically 
possible that the associations between thyroid hormones and menstrual cycle function may 
differ by proximity to menopause. Given the wide age range in this study, upon further 
review, two women may have been perimenopausal (one woman aged 52 years was 
amenorrheic during the study and another aged 54 years had consistently short cycles). 
However, both women showed hormonal evidence of ovulation and when excluded, were not 
influential observations in analyses. Future studies with larger sample sizes may consider 
stratifying by age to evaluate whether thyroidal impacts on menstrual cycle function may 
vary. Second, serum reproductive hormones were not measured; instead relying on urinary 
FSH and metabolites of estrogen and progesterone. Although these are less clinically 
interpretable, this made it possible to obtain serial measures every day over a three-month 
period, resulting in comprehensive data on menstrual cycle function.
Third, a potentially important caveat to this research is that although particular thyroid 
hormones were associated with certain menstrual cycle function outcomes, it is possible that 
these associations are not independent due to the thyroid’s negative feedback loop which 
results in functional relationships between hormones.35 Therefore, the observed associations 
with each thyroid hormone may not be isolated and, rather, the ability to detect certain 
associations over others is likely related to low statistical power given the limited sample 
size. Furthermore, because the measurement of menstrual cycle function was comprehensive 
and included both cycle characteristics and hormone measurements, this allowed the fitting 
of several models that tested associations between multiple thyroid hormones and a vast 
array of menstrual cycle function outcomes. This allowed the opportunity to observe 
whether there was consistency among measures within and across menstrual cycles and look 
for overall patterns of associations between the interrelated exposures and outcomes.
Conclusions
Thyroid hormone levels within the euthyroid range were associated with several menstrual 
cycle function outcomes among a sample of healthy premenopausal women. In particular, T4 
and T3 were positively related to urinary estrogen and progesterone metabolite levels across 
the menstrual cycle. This suggests that even within normal ranges, thyroid hormones may 
exert effects on the female reproductive system, perhaps through mechanisms involving 
gonadotropins and steroid hormones, specifically estrogens and progesterone. This research 
contributes to furthering the understanding of the relationships between thyroid function, 
menstrual and reproductive physiology, and the endocrine axes that govern each.
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(panels C and D) levels across the menstrual cycle by total T4 concentrations.
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Table 1
Characteristics of 86 premenopausal euthyroid women in the Michigan Polybrominated Biphenyl Registry 
menstrual cycle function study by thyroid hormone levelsa (2004–2014)
N (%) TSH (μIU/ml) Total T4 (μg/dl)
Age (years)b
 18–25 8 (9.3) 1.4 8.0
 26–30 7 (8.1) 1.3 9.7
 31–35 11 (12.8) 1.6 9.3
 36–40 35 (40.7) 1.6 9.2
 41–45 9 (10.5) 1.5 8.1
 46–54 16 (18.6) 1.1 9.2
Education
 High school 13 (15.3) 1.4 8.9
 Some college or technical school 40 (47.1) 1.4 9.0
 College graduate or more 32 (37.7) 1.5 9.1
 Missing 1
Income
 <$50,000/year 41 (48.2) 1.5 9.0
 ≥$50,000/year 44 (51.8) 1.4 9.0
 Missing 1
Parity
 0 prior pregnancies 19 (22.1) 1.5 8.6
 1–2 prior pregnancies 28 (32.6) 1.5 9.1
 3 or more prior pregnancies 39 (45.4) 1.4 9.2
Body mass index categoryc
 Normal 34 (39.5) 1.6 8.8
 Overweight 23 (26.7) 1.4 9.0
 Obese 29 (33.7) 1.3 9.3
Smoking statusd
 Never smoker 51 (59.3) 1.5 9.1
 Former smoker 12 (14.0) 1.2 9.2
 Current smoker 23 (26.7) 1.4 8.8
Study phase
 2004–2006 30 (34.9) 1.8 9.5
 2013–2014 56 (65.1) 1.3 8.8
Average behavior over study period
Weekly Exercise
 0 times 28 (32.6) 1.3 9.3
 1–3 times 29 (33.7) 1.6 8.8
 >3 times 29 (33.7) 1.5 8.9
Stresse
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N (%) TSH (μIU/ml) Total T4 (μg/dl)
 Low 27 (31.4) 1.5 8.9
 Moderate 32 (37.2) 1.4 8.6
 High 27 (31.4) 1.4 9.6
Daily Smoking
 None 63 (73.3) 1.5 9.1
 1–9 cigarettes/day 12 (14.0) 1.4 9.3
 ≥10 cigarettes/day 11 (12.8) 1.4 8.4
Weekly alcohol consumption
 0 servings 25 (29.1) 1.2 9.0
 1–3 servings 42 (48.8) 1.6 9.2
 ≥4 servings 19 (22.1) 1.5 8.7
a
Geometric means calculated for TSH, arithmetic means calculated for total T4
b
Age when participant started the menstrual cycle function study
c
Body mass index (kg/m2) =weight (lb)/[height (in)]2 × 703 and defined as: normal: 18.5–24.9; overweight: 25.0–29.9; obese: ≥30.0
d
Based on the questionnaire responses and daily diaries during the study
e
Stress determination is based on a combination of duration and intensity
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